Home › Therapeutic areas › Metabolic › MASH
MASH (7 companies)
Companies with an active program in MASH.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 1 | Phase 3 | $405M | 3 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 2 | NDA Submitted | $6.21B | 6 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 1 | Phase 2 | $10.6M | 4 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $191M | 7 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | 1 | Phase 3 | $698M | 3 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 1 | Phase 3 | $3.42B | 9 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $665M | 5 |
No companies match.